ब्यूप्रेनॉर्फिन और सेलेजिलिन का इंटरैक्शन

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ].

Intervention: The use of BELBUCA is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.

Serotonergic Drugs : Concomitant use may result in serotonin syndrome.

Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.

Monoamine Oxidase Inhibitors (MAOIs) : Can potentiate the effects of buprenorphine.

ZELAPAR is contraindicated in patients with: • Concomitant use of opioid drugs (e.g., meperidine, tramadol, or methadone).

ZELAPAR is contraindicated in patients using the following drugs: opioid drugs (e.g., meperidine, tramadol, methadone), MAO inhibitors including selective MAO-B inhibitors, dextromethorphan, St.

Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 )] .